Status: Recruiting
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.
Participants needed: 23
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: SynAct Pharma ApsUpdated: Mar 6, 2026Locations: 1
Eligibility criteria
Written informed consent has been obtained prior to initiating any study-specifi... [+8]
Participation in any other study involving investigational drug(s) during the st... [+12]